Trial record 1 of 1 for:    NCT01012817
Previous Study | Return to List | Next Study

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

This study has suspended participant recruitment.
(this study will temporarily close while patients at Dose Level 13 (400 mg ABT-888 twice daily; 3 mg/m2 Topotecan) are assessed per study design.)
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01012817
First received: November 11, 2009
Last updated: September 16, 2014
Last verified: August 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)